Notably, abnormalities in the cyclin D1-CDK4/6 complex have been implicated in 35–90% of melanomas, and their oncogenic alterations are associated with decreased survival and therapeutic resistance [8, 9]. This evidence concerns the gene CDK4 and melanoma.